Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07690371 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Phase 3 study, sponsored by Nektar Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
NCT07690371 is a Phase 3 study that is actively recruiting participants, run by Nektar Therapeutics. The registered enrollment target is 510 participants.
The verdict
NCT07690371, a Phase 3 study, is actively recruiting participants, sponsored by Nektar Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
Study Summary
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.
Interventions
- DRUG Placebo
- DRUG Rezpegaldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07690371
The ClinicalTrials.gov registry entry for NCT07690371 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07690371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07690371 about?
NCT07690371 is a clinical study titled "A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis". This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approxima...
What is the current status of trial NCT07690371?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2026-07. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07690371?
The interventions under investigation include: Placebo (DRUG), Rezpegaldesleukin (DRUG).
Who is sponsoring clinical trial NCT07690371?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.